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Background: Type 2 diabetes is a common and costly illness, associated with significant morbidity and mortality.
Despite this, there is relatively little information on the ‘real-world’ medication utilization patterns for patients with
type 2 diabetes initiating exenatide BID or glargine. The objective of this study was to evaluate the ‘real-world’
medication utilization patterns in patients with type 2 diabetes treated with exenatide BID (exenatide) versus insulin
glargine (glargine).
Methods: Adult patients( ≥18 years of age) with type 2 diabetes who were new initiators of exenatide or glargine
from October 1, 2006 through March 31, 2008 with continuous enrollment for the 12 months pre- and 18 months
post-index period were selected from the MarketScan® Commercial and Medicare Databases. To control for
selection bias, propensity score matching was used to complete a 1:1 match of glargine to exenatide patients. Key
study outcomes (including the likelihood of overall treatment modification, discontinuation, switching, or
intensification) were analyzed using survival analysis.
Results: A total of 9,197 exenatide- and 4,499 glargine-treated patients were selected. Propensity score matching
resulted in 3,774 matched pairs with a mean age of 57 years and a mean Deyo Charlson Comorbidity Index score
of 1.6; 54% of patients were males. The 18-month treatment intensification rates were 15.9% and 26.0% (p < 0.0001)
and the discontinuation rates were 38.3% and 40.0% (p = 0.14) for exenatide and glargine, respectively. Alternatively,
14.9% of exenatide-treated patients switched therapies, compared to 10.0% of glargine-treated patients (p < 0.0001).
Overall, glargine-treated patients were more likely to modify their treatment [hazard ratio (HR) = 1.33, p < 0.0001] with
shorter mean time on treatment until modification (123 vs. 159 days, p < 0.0001). Compared to exenatide-treated
patients, glargine-treated patients were more likely to discontinue [hazard ratio (HR) = 1.25, p < 0.0001] or intensify
therapy (HR = 1.72, p < 0.0001) but less likely to switch (HR = 0.71, p < 0.0001) the index therapy.
Conclusions: Patients treated for type 2 diabetes with exenatide BID or insulin glargine differ in their adherence to
therapy. Exenatide-treated patients were less likely to discontinue or modify treatment but more likely to switch
therapy compared to glargine-treated patients.* Correspondence: machaon.bonafede@truvenhealth.com
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Diabetes is a leading cause of morbidity and mortality in
the United States [1] and is a key independent risk factor
for a number of microvascular and macrovascular diseases.
According to the American Diabetes Association (ADA)
and European Association for the Study of Diabetes (EASD)
Consensus Statement, type 2 diabetes is characterized by
progressive loss of beta cell function and a corresponding
need for progressive and early addition of glucose lowering
strategies [2]. Achieving and maintaining glycemic control
as a primary treatment goal for the management of type 2
diabetes is challenging.
Several studies have examined glucose lowering treat-
ment patterns for type 2 diabetes, showing suboptimal
use and poor adherence/persistency with current therap-
ies [3-5]. Failure to continue their glucose lowering
medications may be associated with adverse outcomes
including both clinical as well as economics conse-
quences. The Third National Health and Nutrition
Examination Survey found that many patients with type
2 diabetes fail to achieve optimal glycemic control
and are at increased risk of developing complications
[6]. A review article by Cramer reported that poor
adherence to glucose lowering medications may lead
to suboptimal glycemic control and also be associated
with increased healthcare resource utilization and costs
(e.g. due to hospitalizations, temporary or permanent
disability because of diabetes related complications) [7].
Stuart et al. reported a positive relationship between
persistency to glucose lowering medication and decreased
healthcare costs and lower hospitalization rates [8].
Inadequate glycemic control may signal the need for
assessment and treatment modification. In order to
improve patient outcomes, it is essential to understand
the medication use behavior of comparatively newer
therapies such as exenatide BID (exenatide), a glucagon
like peptide 1 (GLP-1) receptor agonist and insulin
glargine (glargine) for the treatment of type 2 diabetes.
Although, the clinical efficacy of both exenatide and
glargine are well established, there is little information
available on the ‘real-world’ economic and medication
utilization patterns of these therapies. Hence, drug
utilization studies using administrative pharmacy claims
data can provide useful insights into the prescribing
patterns and patient medication-taking behavior for
exenatide and glargine in usual-care settings.
The goal of this retrospective observational study
was to understand more clearly the progression of
treatment patterns for patients initiating exenatide or
glargine using an evaluation of the rates, timing and
likelihood of treatment modification. This information
may be particularly useful for health plans and providers
planning interventions aimed at improving patient
glycemic control and other health outcomes.Methods
Study design
A retrospective, observational study was conducted, using a
large managed care claims database that comprised of
patients with type 2 diabetes initiating exenatide or
glargine treatment. Data were derived from the
MarketScan® Commercial Claims and Encounters
(Commercial) Database and the Medicare Supplemental
and Coordination of Benefits (COB) (Medicare) Database.Patient selection
Patients aged 18 years and older with at least one pre-
scription claim for exenatide or glargine from October 1,
2006 through March 31, 2008 were selected and screened
for continuous eligibility for the 12 months pre- and
18 months post-index period. The index date was defined
as the date of the first exenatide or glargine prescription
in the above time window.
To ensure the inclusion of only patients with type 2
diabetes, patients were excluded if they had a medical
claim with a diagnosis code for gestational diabetes or
type 1 diabetes. Patients with diagnosis code for chronic
kidney disease, Cushing syndrome, acromegaly, a gastric
bypass or banding procedure or occurrence of ≥2
prescription claims for a systemically administered
glucocorticoid were also excluded. Patients who
lacked a pharmacy benefit or transitioned from the
Commercial to Medicare database during the pre- and
post-index were also excluded in order to appropriately
track their medication use patterns. Patients with any of
the following prescriptions in the pre-index period were
excluded: pramlintide, sitagliptin, exenatide or insulin
(including glargine). Study diagnosis, procedure, and drug
codes are available from the authors.Outcomes measurement
Variables
Demographic variables included gender, age, geographic
region, and health plan type. Clinical variables measured
included the presence of diabetes related microvascular
complications (diabetic retinopathy and macular edema;
diabetic neuropathy; amputation and ulceration; renal
disease) and macrovascular complications (myocardial
infarction; ischemic heart disease; congestive heart fail-
ure; peripheral vascular disease; cerebrovascular disease)
and presence of common comorbidities (hypertension;
dyslipidemia; depression; obesity; hypoglycemia). The
Deyo Charlson Comorbidity index (CCI) [9] score
was calculated to measure the severity of comorbid
conditions. The study also captured the provider
specialty, pre-index use of medications, average number
of prescriptions and average number of drug classes
administered by patients.
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Treatment modification in the matched cohorts was
defined as the first event of change in the index
medication in the 18 months post-index period and
was classified further into 3 types: intensification, switching
or discontinuation of the index medication.
Discontinuation was defined as a 90-day gap following
the end of the days’ supply of the previous prescription
claim for an index medication, without any other
prescription for a non-index glucose-lowering therapy
in that 90-day gap. Switching was defined as a prescription
claim for a non-index glucose lowering medication without
a refill of the index medication in the 90 days following the
end of the days’ supply of the previous claim for the index
prescription, with at least one refill of the new glucose
lowering medication in the 90 days. Intensification was
defined as the addition of a non-index glucose-lowering
medication; continuation of a pre-index medication does
not qualify as intensification. Additions were indicated by a
non-index glucose-lowering medication prescription
with overlap of its days’ supply with that of the index
medication, followed by refills of the index medication
and the added medication in the 90 days following the
end of the days’ supply specific to each medication.
Exenatide intensification was indicated by the addition
of a new glucose-lowering medication while glargine
intensification was indicated by the addition of a new
glucose-lowering medication or by a dose increase of
at least 100%. The definition for intensification was
modified for glargine as glargine dose is escalated upwards
before adding any new medication. Dose was calculated
for each glargine prescription by dividing the total insulin
units dispensed for a prescription by the number of
elapsed days between that dispense date and the next, as
the actual dose of insulin prescribed is not recorded in the
claims database.
Treatment durability was functionally defined as the
absence of treatment modification and is measured as the
time on index treatment without treatment modification
(such as switching, intensifying, or discontinuing).
Analysis
Propensity score matching process
Because this was an observational study and randomization
of patients is not possible, propensity score matching was
used to ensure a similar distribution of specific characteris-
tics between the exenatide and glargine patients. Propensity
score matching reduces selection bias that might arise
when comparing two different treatment options. Variables
used in the 1:1 matching included the baseline characteris-
tics listed in Table 1: gender, age, geographic region, health
plan type, CCI score, diabetes related complications,
other common comorbidities, physician specialty, use
of glucose lowering medications (not including bloodglucose self-monitoring devices) and cardiovascular
medications and healthcare resource use in the pre-index
period.
Categorical variables were summarized by frequency
and percentages. Continuous variables were reported
by mean and standard deviation. Differences between
treatments were tested for statistical significance using
chi-square tests for categorical variables and t-tests
or Wilcoxon rank tests for continuous variables.
Kaplan-Meier plots were constructed to illustrate the
probability of treatment modification for overall as
well as each of the three modification measures in
the post index period. Log-rank statistics and survival
analysis were performed to assess the significance of
the difference between treatments.
The data used for this study was based on an existing
administrative health insurance claims database. There
was no interaction with any subjects and the database
does not include any individually identifiable data (e.g. does
not include names, addresses, social security or medical
record numbers, or any other obvious identifiers). The data
is not developed or reported in a way that subjects can be
identified, directly or through identifiers linked to subjects.
According to information provided by the Office for
Human Research Protections, this type of data is exempt
for an IRB review under the requirements of the US
Department of Health and Human Services regulations 45
CFR part 46. We acknowledge that many academic and
medical institutions may have local IRBs that mandate that
retrospective database studies apply for an IRB exemption;
in this case there was no such mandate.
Results
Demographic and clinical characteristics
A total of 9,197 exenatide and 4,499 glargine patients
met all inclusion and exclusion criteria in the pre-index
period, prior to propensity score matching (Table 1).
Propensity score matching resulted in a total of 3,774
matched pairs in the pre-index period. Baseline patient
characteristics, including age, gender, health plan,
clinical and resource use variables were balanced
between the 2 cohorts after matching, with post-match
standardized differences of less than 2.5 for all measures
except age. Mean age in the exenatide cohort was 57.0
(standard deviation (SD = 10.8) years, compared to 57.8
(SD = 12.0) years in the glargine cohort (standardized
difference = 7.8). Pre- and post-match descriptive measures
are reported in Table 1.
Treatment modification
Compared to exenatide-treated patients, glargine-treated
patients had lower treatment durability, demonstrated
by higher rates of treatment modification and shorter
time to treatment modification. Glargine-treated patients





Patients treated with Patients treated with
Exenatide BID Insulin glargine Exenatide BID Insulin glargine
N = 9,197 N = 4,499 N = 3,774 N = 3,774
N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD Std. diff.
Age: mean (years) 54 10 59 12 < 0.0001 57 10 57 12 7.8
Age: group < 0.0001
18-34 267 2.9% 72 1.6% 71 1.9% 66 1.7% 1.0
35-44 1,183 12.9% 397 8.8% 368 9.8% 381 10.1% 1.2
45-54 3,135 34.1% 1,146 25.5% 1,077 28.5% 1,073 28.4% 0.2
55-64 3,307 36.0% 1,382 30.7% 1,289 34.2% 1,272 33.7% 1.0
65+ 1,305 14.2% 1,502 33.4% 969 25.7% 982 26.0% 0.8
Sex: female 5,359 58.3% 1,948 43.3% < 0.0001 1,720 45.6% 1,726 45.7% 0.3
Diabetes complications
Microvascular 1,521 16.5% 1,109 24.6% < 0.0001 769 20.4% 766 20.3% 0.2
Macrovascular 1,530 16.6% 1,349 30.0% < 0.0001 879 23.3% 906 24.0% 1.7
Deyo charlson
Comorbidity index
1.4 1.1 1.8 1.5 < 0.0001 1.6 1.3 1.6 1.3 0.1
Medication claims 41.2 25.1 40.8 27.2 0.37 41.0 24.9 40.4 26.9 2.2
Medication classes 9.9 4.4 9.9 4.7 0.60 9.7 4.2 9.8 4.6 1.5
Pre-index inpatient admissions 815 8.9% 952 21.2% < 0.0001 530 14.0% 543 14.4% 1.0
Pre-index total healthcare costs $9,749 $12,251 $14,536 $31,763 < 0.0001 $11,194 $15,747 $11,245 $18,254 0.3
Physician specialty < 0.0001
Primary care 6,346 69.0% 3,170 70.5% 2,722 72.1% 2,699 71.5% 1.4
Endocrinology 1,168 12.7% 210 4.7% 204 5.4% 198 5.2% 0.7
Other specialist 1,016 11.0% 680 15.1% 524 13.9% 529 14.0% 0.4
Missing/unknown 667 7.3% 439 9.8% 324 8.6% 348 9.2% 2.2
Treatment pre-Index
Glucose lowering 9,188 99.9% 4,402 97.8% < 0.0001 3,765 99.8% 3,766 99.8% 0.6
Biguanides (metformin) 6,761 73.5% 2,940 65.3% < 0.0001 2,624 69.5% 2,626 69.6% 0.1
Sulfonylureas 4,252 46.2% 3,011 66.9% < 0.0001 2,445 64.8% 2,428 64.3% 0.9
Meglitinides 466 5.1% 259 5.8% 0.090 212 5.6% 216 5.7% 0.5
Thiazolidinediones 4,688 51.0% 2,382 52.9% 0.030 2,085 55.2% 2,082 55.2% 0.2
α glucosidase inhibitors 92 1.0% 69 1.5% 0.0065 44 1.2% 53 1.4% 2.1
Fixed dose therapies 2,293 24.9% 916 20.4% < 0.0001 854 22.6% 840 22.3% 0.9
Cardiovascular 8,493 92.3% 4,111 91.4% 0.049 3,470 91.9% 3,463 91.8% 0.7
Antihyperlipidemics 6,526 71.0% 3,074 68.3% 0.0016 2,648 70.2% 2,638 69.9% 0.6
Antihypertensives 7,693 83.6% 3,814 84.8% 0.091 3,183 84.3% 3,187 84.4% 0.3
Other 3,164 34.4% 1,308 29.1% < 0.0001 1,089 28.9% 1,106 29.3% 1.0
Antidepressants 2,890 31.4% 1,138 25.3% < 0.0001 952 25.2% 978 25.9% 1.6
Antiobesity 82 0.9% 10 0.2% < 0.0001 9 0.2% 10 0.3% 0.5
Antiemetics/antinausea 429 4.7% 260 5.8% 0.0051 202 5.4% 203 5.4% 0.1
1 Post-match balance was assessed by evaluating the standardized difference (std. diff.). All standardized differences were less than 2.5, except for mean age,
which was 7.8.
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(HR) = 1.33, p < 0.0001]. Compared to exenatide-treated
patients, a significantly higher percentage of glargine-
treated patients experienced treatment modification in the
18 months post-index period (Table 2 and Figure 1). By
18 months, treatment modification was observed in 76.0%
of the glargine cohort vs. 69.1% of the exenatide cohort
(p < 0.0001). Patients initiating exenatide, were on
their treatment longer before any modification compared
to glargine-treated patients (159 vs. 123 days, p < 0.0001)
indicating longer treatment durability.
Glargine-treated patients were 72% more likely to
intensify therapy (HR = 1.72, p < 0.0001), with 26% of
the glargine cohort vs. 15.9% of the exenatide cohort
(p < 0.0001) having intensified by 18 months. The
average time until treatment intensification was similar
between exenatide and glargine patients (150 days vs. 154
days, p = 0.541). Similarly, there was a 25% greater
likelihood of discontinuation of therapy in the
glargine vs. exenatide cohorts (HR = 1.25, p < 0.0001).
The average time until discontinuation was 156 days for





Any type of treatment modification (Discontinuation, switching, or inte
By day 180 of follow-up 1,629 44
By day 365 of follow-up 2,284 62
By day 545 of follow-up 2,515 69
Mean days to modification† 159 1
Intensification
By day 180 of follow-up 394 10
By day 365 of follow-up 538 14
By day 545 of follow-up 580 15
Mean days to intensification† 150 1
Discontinuation
By day 180 of follow-up 902 24
By day 365 of follow-up 1,264 34
By day 545 of follow-up 1,394 38
Mean days to discontinuation† 156 1
Switching
By day 180 of follow-up 333 9
By day 365 of follow-up 482 13
By day 545 of follow-up 541 14
Mean days to switching† 177 1
* Patients with incomplete or invalid data on pharmacy claims were dropped; matc
† Mean days were calculated among patients with the specified modification.patients (p < 0.0001). Switching was the only treatment
modification less likely to occur with glargine relative to
exenatide-treated patients (HR = 0.71, p < 0.0001). However,
among patients who did switch therapies, the average time
until switching treatments was longer for exenatide-treated
patients (177 days) compared to insulin glargine-treated
patients (125 days, p < 0.0001).
Within the exenatide cohort, the most commonly
used drug for intensification was biguanides (34.3% of
patients with intensification), followed by sulfonyl-
ureas (18.3%) (Table 3). Glargine was used in only
8.3% of patients who initiated exenatide. Within the
glargine cohort, intensification was most often accom-
plished by increasing the glargine dose (28.0%), followed
by use of non-glargine insulin (21.1%). Intensification
with exenatide was observed in only 5.9% of patients
who initiated with glargine. Exenatide-treated patients
who switched most often switched to sitagliptin
(27.0%) or glargine (20.9%), whereas glargine-treated
patients switched to a non-glargine insulin (27.1%),
sulfonylureas (13.7%), biguanides (13.4%), or exenatide





.7% 2,169 59.6% < 0.0001
.7% 2,616 71.8% < 0.0001
.1% 2,768 76.0% < 0.0001
23 123 112 < 0.0001
.8% 660 18.1% < 0.0001
.8% 856 23.5% < 0.0001
.9% 947 26.0% < 0.0001
17 154 128 0.541
.8% 1,163 31.9% < 0.0001
.7% 1,396 38.3% 0.0013
.3% 1,456 40.0% 0.14
24 111 105 < 0.0001
.1% 304 8.3% 0.23
.2% 340 9.3% < 0.0001
.9% 365 10.0% < 0.0001
25 125 112 < 0.0001
hed controls for these patients were also dropped.
Any Modification Discontinuation
SwitchingIntensification









Figure 1 Treatment modification: Kaplan-Meier curves.
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There is little information on the ‘real-world’ medication
utilization patterns for patients with type 2 diabetes
initiating exenatide BID or glargine. The strength of this
study is that it provides the ‘real-world’ data on
physician prescribing behavior and patient medication
use behavior over 18 months follow-up period in usual
care settings. These observations used robust statistical
approaches including propensity analyses to insure that the
groups being compared were similar at baseline. In the
current retrospective observational study, exenatide-treated
patients had greater treatment durability as mea-
sured by a lower probability of treatment modifica-
tion and a longer time to treatment modification.
Glargine-treated patients were 33% more likely to
modify (discontinue, intensify or switch) their treat-
ment compared to exenatide-treated patients over
the 18-month post-index period showing a consistent
and steady difference, favorable to exenatide. The
findings of this study are significant given the ongoing
challenges associated with managing patients on therapies
such as insulin or exenatide for achieving and maintaining
glycemic control [10,11].
Treatment management for diabetes is often subopti-
mal, characterized by high rates of discontinuation, non-
adherence, and lack of treatment modification [12], all
of which are potential indicators of inadequate disease
management including suboptimal glycemic control. Lower
rates of persistence with insulin among new users are well-established; for example Cooke et al. reported that only
28.7% of new insulin users were persistent at 12 months
[10]. In addition, a review article by Stephens et al. reported
that better treatment persistence was associated with lower
rates of diabetes-related complications, and also with
reduced healthcare costs [13].
In the current study, exenatide-treated patients were
less likely to discontinue or intensify treatment com-
pared to glargine-treated patients. This is consistent
with previously published reports by Fabunmi et al.
[11] and Segal et al. [14]. Fabunmi et al. found that,
compared to patients treated with glargine, exenatide-
treated patients had a higher medication adherence (68.4%
vs. 57.9%, p < 0.001), were more likely to have an adherence
of at least 80% (46.9% vs. 29.4%, p < 0.001), and less likely
to have either a 60 or 90-day gap in therapy (p < 0.001).
This current study did not examine reasons for treat-
ment modification and there are multiple hypotheses as
to why responses to or treatment patterns with these
therapies might differ. For example, weight gain and
hypoglycemia have been reported as significant reasons
for discontinuation/switching of insulin therapy among
patients with type 2 diabetes [15]. By contrast, exenatide
has been shown to reduce patient weight [16-18],
without increasing the risk of hypoglycemia common to
several other glucose-lowering therapies [19]. In addition,
the higher discontinuation rate without switching to
another medication in glargine-treated patients could be
due to tolerance issues or poor compliance; alternatively,
Table 3 Treatment modification: specific drugs used in
switching and intensification
Drug Patients treated with
Exenatide BID Insulin glargine
N = 3,642* N = 3,642*
N %† N %†
Modification: Intensification 580 100% 947 100%
Exenatide BID 0 0.0% 56 5.9%
Insulin glargine 48 8.3% 265 28.0%
Dose increased at least 100% 92 9.7%
Other insulin 28 4.8% 200 21.1%
Pre-mixed 2 0.3% 13 1.4%
Bolus 3 0.5% 184 19.4%
Basal (other than glargine) 23 4.0% 3 0.3%
Oral
Sitagliptin 41 7.1% 65 6.9%
α glucosidase inhibitors 1 0.2% 1 0.1%
Thiazolidinediones 67 11.6% 85 9.0%
Meglitinides 14 2.4% 24 2.5%
Sulfonylureas 106 18.3% 78 8.2%
Biguanides 199 34.3% 114 12.0%
Fixed dose therapies 76 13.1% 54 5.7%
Other injectable/pramlintide 0 0.0% 5 0.5%
Modification: switching 541 100% 365 100%
Exenatide BID 0 0.0% 48 13.2%
Insulin glargine 113 20.9% 0 0.0%
Other insulin 65 12.0% 99 27.1%
Pre-mixed 17 3.1% 55 15.1%
Bolus 15 2.8% 23 6.3%
Basal (other than glargine) 33 6.1% 21 5.8%
Oral
Sitagliptin 146 27.0% 31 8.5%
α glucosidase inhibitors 2 0.4% 0 0.0%
Thiazolidinediones 39 7.2% 46 12.6%
Meglitinides 8 1.5% 9 2.5%
Sulfonylureas 45 8.3% 50 13.7%
Biguanides 69 12.8% 49 13.4%
Fixed dose therapies 52 9.6% 33 9.0%
Other injectable/Pramlintide 2 0.4% 0 0.0%
* Patients with incomplete or invalid data on pharmacy claims were dropped;
matched controls for these patients were also dropped.
† Percentages were calculated among patients with the specified modification.
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function. Other potential reasons for treatment modifica-
tion could be due to factors unrelated to improved
glycemic control, such as cost or convenience. In addition,
exenatide is a fixed dose therapy while glargine requiresdose adjustment. Most patients who initiate glargine with
low dose of 10 units per day would require an increase in
dose to reach to the average dose of 30-40 units per
day; this could be another reason that may influence
treatment modification. In order to reduce this bias,
the dose increase of 100% or more is considered as
treatment modification for glargine patients. This
study also found that glargine-treated patients were
less likely to switch treatments than exenatide-treated
patients (HR:0.71, p < 0.0001), which could be due, in
part, to poorer tolerability of exenatide compared to
insulin glargine. However, the exact reasons for treatment
modifications cannot be identified with certainty from the
current study and claims database.
Like any retrospective database analyses, this study has
some limitations. First, the database comprised patients
with commercial insurance coverage and results may not
be generalizable to other patient populations. Second,
clinical measures of glycemic control such as HbA1c or
hypoglycemia and disease duration or severity are not avail-
able in this dataset. In the absence of HbA1c, diabetes-
related complications, comorbidities and medication use in
the pre-index period were used as a proxy to control for
severity of disease in propensity score matching. Other
variables impacting diabetes control, such as duration of
diabetes, body weight/body mass index and adherence with
life style modifications were not available in the database.
Third, treatment modification measures were based on the
presence or absence of prescription claims. These measures
do not provide record of when or if medications were actu-
ally used; as such, this is an analysis of prescription filling
patterns and not necessarily patient medication utilization
behavior. Similarly, actual dose of insulin prescribed was
not recorded in the claims database. Insulin glargine dose
was calculated based upon insulin units dispensed and
prescription refill dates, potentially leading to an overesti-
mation of the quantity of insulin used by patients. Treat-
ment intensification due to increased glargine dose,
therefore, was defined as a 100% dose increase from one
claim to the next in order to compensate for a potential
overestimation of daily insulin doses. This approach was
chosen to help insure that insulin glargine-treated patients
who refilled their prescriptions early were not misclassified
as patients intensifying treatment. This is the most conser-
vative way of defining dose escalation for glargine in order
to reduce potential bias towards exenatide. Fourth, while
propensity score matching was used to reduce potential
selection bias, and create two comparable patient groups, it
does not control for potential unmeasured confounding
variables. Also, the study only followed patients for
18 months following treatment initiation so adverse events
(and related treatment modification) occurring after
18 months are not captured in this current analysis; it is
unclear if longer term tolerability issues would have a
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Limited information is available about the healthcare
professionals that patients interact with, including
prescribing physician speciality, educational programs,
or medication therapy management initiatives often
conducted by pharmacists or diabetes educators. This
current analysis could not assess the presence of these
resources or if access to them was different by study cohort.
Lastly, it is important to note that the observational nature
of the study design does not permit causal inferences.
Conclusions
In conclusion, this study provides ‘real-world’ data showing
significant differences in treatment modification rates for
exenatide BID and insulin glargine, indicating potential for
longer treatment durability for patients initiating exenatide
BID. Future research should also examine the basis for the
better medication utilization patterns associated with
exenatide BID and whether those patterns translate into
better clinical and economic outcomes.
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